Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256433 | 0.90 | HTR2C (0.44) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL19256434 | 0.86 | HTR2C (0.46) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL14209722 | 0.85 | HTR2C (0.53) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL19256435 | 0.84 | HTR2C (0.44) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL703547 | 0.83 | SMN1; SMN2 (0.48) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL5765399 | 0.83 | SMN1; SMN2 (0.48) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL21193204 | 0.82 | HTR2C (0.45) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL28644186 | 0.81 | AGTR2 (0.54) | HTR2CAGTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21192898 | 0.80 | HTR2C (0.43) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 | |
| SCHEMBL31421166 | 0.79 | RIPK1 (0.44) | HTR2CNPC1RAB9ASMN1; SMN2PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2022-09-06 | — | — | US | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109219606-B | Halogen substituted piperidines as orexin receptor modulators | 阿斯利康(瑞典)有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
| US-20150307458-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HTR2C 32/4885AGTR2 75/4885NPC1 1644/4885 |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HTR2C 32/4885AGTR2 75/4885NPC1 1644/4885 |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HTR2C 32/4885AGTR2 75/4885NPC1 1644/4885 |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HTR2C 32/4885AGTR2 75/4885NPC1 1644/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HTR2C 32/4885AGTR2 75/4885NPC1 1644/4885 |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HTR2C 32/4885AGTR2 75/4885NPC1 1644/4885 |
| US-20150307458-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | HTR2C 1/4885AGTR2 574/4885NPC1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.